Cadrenal Therapeutics CVKD
NASDAQ CVKD
$0.97 -0.11 (-10.19%)
At close: Oct 1, 2026 · 4:00 PM EDT

Cadrenal Therapeutics (CVKD) Return on Equity [ROE] (2023 - 2026)

Updated

Cadrenal Therapeutics (CVKD) posted Return on Equity [ROE] of -400.44% for Q2 2026, down 205.83 percentage points from -194.61% a year earlier.

Analysis

Cadrenal Therapeutics (CVKD) Return on Equity [ROE] (2023 - 2026) Analysis & Trends

For FY2023, Cadrenal Therapeutics' Return on Equity [ROE] came in at -689.68%.

  • The Q2 2026 figure stands as the lowest quarterly Return on Equity [ROE] in data going back to Q2 2023.
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) ROE (Qtr)
1 Johnson & Johnson 638.12 Bn 556.64 Bn 17.26 Bn 25.32%
2 AbbVie 462.60 Bn 435.75 Bn 12.70 Bn -
3 Merck 358.70 Bn 313.13 Bn 12.21 Bn 7.21%
4 Novartis Ag 272.16 Bn 228.03 Bn 11.24 Bn 84.40%
5 Astrazeneca 250.36 Bn 223.92 Bn 12.86 Bn 21.39%
6 Amgen 227.87 Bn 183.27 Bn 7.24 Bn 83.75%
7 Gilead Sciences 184.97 Bn 159.08 Bn 6.22 Bn -18.38%
8 Pfizer 162.61 Bn 109.56 Bn 10.94 Bn 4.97%
9 Vertex Pharmaceuticals 132.45 Bn 104.46 Bn 2.84 Bn 22.24%
10 Cadrenal Therapeutics 3.35 Mn -9.27 Mn - -400.44%
Historic Data

Historic Data

Download Data
DateValue
Jun 30, 2026 -400.44%
Jun 30, 2025 -194.61%
Sep 30, 2024 -205.50%
Jun 30, 2024 -122.48%
Mar 31, 2024 -69.82%
Dec 31, 2023 -89.88%
Sep 30, 2023 -123.09%
Jun 30, 2023 -201.27%
API Access

Cadrenal Therapeutics Return on Equity [ROE] API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=return-on-equity-%5Broe%5D&ticker=CVKD&period=max&api_key=YOUR_API_KEY